A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | MicrobiomeTrials
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2024-02-20Est. Completion: 2027-04-10
Enrollment target: 87 participants
Locations
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center, Coral Gables, Florida, United States
University of Miami Hospital and Clinics Deerfield Beach, Deerfield Beach, Florida, United States
Sylvester Comprehensive Cancer Center- Doral, Doral, Florida, United States
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
University of Miami Hospital and Clinics, Miami, Florida, United States
Sylvester Comprehensive Cancer Center Kendall, Miami, Florida, United States
Sylvester Comprehensive Cancer Center Plantation, Plantation, Florida, United States
Emory University Hospital Midtown, Atlanta, Georgia, United States
Emory University Hospital, Atlanta, Georgia, United States
Winship Cancer Institute, Atlanta, Georgia, United States
Indiana CTSI Clinical Research Center (ICRC), Indianapolis, Indiana, United States
Indiana University Health University Hospital, Indianapolis, Indiana, United States
Indiana University Melvin and Bren Simon Comprehensive Cancer Center (IUSCCC), Indianapolis, Indiana, United States
University of Maryland, Baltimore, Maryland, United States
Other microbiome trials you might be interested in